ShanXi C&Y Pharmaceutical GroupLTD Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for ShanXi C&Y Pharmaceutical GroupLTD.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 19.3% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet
Sep 30
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues
May 27ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues
Mar 25ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Mar 06En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como ShanXi C&Y Pharmaceutical GroupLTD no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 9/30/2024 | 836 | 83 | 13 | 90 | N/A |
| 6/30/2024 | 835 | 83 | 31 | 98 | N/A |
| 3/31/2024 | 806 | 46 | 5 | 80 | N/A |
| 12/31/2023 | 799 | 25 | 4 | 38 | N/A |
| 9/30/2023 | 767 | -107 | 6 | 24 | N/A |
| 6/30/2023 | 790 | -120 | 19 | 44 | N/A |
| 3/31/2023 | 820 | -119 | 13 | 36 | N/A |
| 1/1/2023 | 829 | -119 | 48 | 75 | N/A |
| 9/30/2022 | 847 | -111 | 41 | 82 | N/A |
| 6/30/2022 | 878 | -110 | 44 | 85 | N/A |
| 3/31/2022 | 899 | -94 | 77 | 114 | N/A |
| 1/1/2022 | 930 | -91 | 60 | 97 | N/A |
| 9/30/2021 | 966 | -144 | 34 | 64 | N/A |
| 6/30/2021 | 911 | -191 | 13 | 46 | N/A |
| 3/31/2021 | 920 | -218 | -26 | 12 | N/A |
| 12/31/2020 | 848 | -262 | -52 | -21 | N/A |
| 9/30/2020 | 861 | -162 | -3 | 27 | N/A |
| 6/30/2020 | 968 | -112 | -22 | 0 | N/A |
| 3/31/2020 | 1,029 | -58 | 26 | 42 | N/A |
| 12/31/2019 | 1,132 | 5 | 51 | 70 | N/A |
| 9/30/2019 | 1,184 | 29 | 41 | 45 | N/A |
| 6/30/2019 | 1,154 | 32 | 52 | 67 | N/A |
| 3/31/2019 | 1,119 | 20 | 24 | 43 | N/A |
| 12/31/2018 | 1,136 | 7 | 9 | 38 | N/A |
| 9/30/2018 | 1,092 | 20 | -3 | 28 | N/A |
| 6/30/2018 | 1,058 | 18 | N/A | 35 | N/A |
| 3/31/2018 | 1,024 | 23 | N/A | 43 | N/A |
| 12/31/2017 | 939 | 22 | N/A | 40 | N/A |
| 9/30/2017 | 891 | 25 | N/A | 93 | N/A |
| 6/30/2017 | 834 | 31 | N/A | 64 | N/A |
| 3/31/2017 | 791 | 30 | N/A | 42 | N/A |
| 12/31/2016 | 746 | 30 | N/A | 42 | N/A |
| 9/30/2016 | 732 | 22 | N/A | -15 | N/A |
| 6/30/2016 | 704 | 24 | N/A | 9 | N/A |
| 3/31/2016 | 683 | 22 | N/A | 32 | N/A |
| 12/31/2015 | 684 | 23 | N/A | 15 | N/A |
| 9/30/2015 | 669 | 40 | N/A | 43 | N/A |
| 6/30/2015 | 666 | 40 | N/A | 60 | N/A |
| 3/31/2015 | 660 | 41 | N/A | 56 | N/A |
| 12/31/2014 | 654 | 41 | N/A | 82 | N/A |
| 9/30/2014 | 646 | 38 | N/A | 80 | N/A |
| 6/30/2014 | 598 | 33 | N/A | 72 | N/A |
| 3/31/2014 | 547 | 29 | N/A | 76 | N/A |
| 12/31/2013 | 514 | 27 | N/A | 81 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if 300254's forecast earnings growth is above the savings rate (2.9%).
Beneficios vs. Mercado: Insufficient data to determine if 300254's earnings are forecast to grow faster than the CN market
Beneficios de alto crecimiento: Insufficient data to determine if 300254's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if 300254's revenue is forecast to grow faster than the CN market.
Ingresos de alto crecimiento: Insufficient data to determine if 300254's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 300254's Return on Equity is forecast to be high in 3 years time